Skip to main content
Premium Trial:

Request an Annual Quote

GenVault Raises $13M in VC Funding

NEW YORK (GenomeWeb News) – GenVault has closed a $13 million round of financing with venture capital investors, the Carlsbad, Calif.-based firm said today.
GenVault said that it would use the funds to accelerate commercialization of its technologies for room temperature biosample preservation, storage and distribution for biobanking, translational medicine, and applied testing applications.
The round of financing was led by Montagu Newhall Associates, with additional investments coming from existing investors Domain Associates, QuestMark Partners, and Cross Creek Capital. C. Ashton Newhall, a partner with Montagu Newhall, will join GenVault’s board of directors, the firm said.
GenVault said that its dry state platform “enables the extraction, preservation, recovery, and distribution of DNA at room temperature.” The firm also plans to develop systems for protein and RNA sample management.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.